Avacta Share Discussion Threads

[bonzo] 24/10/2024 11:10

Good to hear from someone else who understands the science!

[pwhite73] 24/10/2024 10:27

Rajraj b - "The CEO had been hinting that big news was on the horizon"

Which CEO are you referring to. The previous one or the current one as both have hinted at 'big news on the horizon'

[rajraj b] 24/10/2024 09:52

As Aman said, keep smoking that crack pipe, you'll soon reach your Nirvana. The CEO had been hinting that big news was on the horizon and that the Science Day will be worth the wait. The company is achieving great things and the treatment of cancer is about take a total about turn in its direction. The path is no longer ADC but the future is now PDC's and AffDC's.

[pwhite73] 24/10/2024 09:44

Lomcovaks - "Today's RNS suggests that Avacta's Pre|cision delivery method is FAR superior to any ADC in the market currently or likely in the future."

That is exactly what it is claiming not merely suggesting. However even the diehards here like tickboo and RajRaj b recognise its a pack of lies.

[lomcovaks] 24/10/2024 09:19

1347,
You'll have to do better fear mongering than that.

When #AVCT first published their 2nd asset AVA3996, a proteosome inhibitor, they announced the estimated market of which was $2.3 Billion dollars by 2026. Press release dated 18th Jan 2022.

On the other hand, the estimated market for Antibody Drug Conjugates in 2026 is over $21 Billion dollars with annual compound growth of 29.57%


Today's RNS suggests that Avacta's Pre|cision delivery method is FAR superior to any ADC in the market currently or likely in the future. .

The board have clearly targeted the correct market. Rather than other candidates 'falling by the wayside', the company is clearly confident that the safety data they have has permitted them to utilize a much more toxic warhead.

I first bought in 2019 and have accumulated ever since. I understand it's super high risk but I don't need unthoughtful comments like yours that don't carry any weight when tested against reality.

[fieldhouse] 24/10/2024 09:15

Looks like a lot of punters prefer CC oncologist expertise to an anonymous bulletin board commentator
Each to his own

[1347] 24/10/2024 08:18

For me it pretty much confirms all their old pipeline has fallen by the wayside and they are back in pre-clinical mode. I'm not being fooled by all this AI fluff either, that's my domain and I can tell you it's being overhyped by a lot of carpet baggers.

[pwhite73] 24/10/2024 07:36

How would you know it was NT to sell unless you were holding?

[dillydally2] 24/10/2024 07:27

Nt to sell now and 62 to buy

[pwhite73] 24/10/2024 07:26

Patio58 - I agree and have said so many times. This is the way to go for the share price. Turn the clock back to the preclinical stage and report fantastic observations and progress.

[dillydally2] 24/10/2024 07:26

Going down now folks

[bbd2] 24/10/2024 07:25

Our first program, AVA6000, demonstrates a four- to six-fold increase in the therapeutic index in the clinic and in preclinical models. With the advances in the platform, we are now seeing a 75-fold increase in therapeutic index with our recently announced exatecan program, AVA6103 in preclinical models, suggesting that AVA6103 could have an unprecedented safety profile in the clinic

[patio58] 24/10/2024 07:22

Must of been a great RNS as the regular doomster on LSE says it's the best RNS Avacta have ever released.

[pwhite73] 24/10/2024 07:17

RNS 24/10/2024 - "The therapeutic index of exatecan is significantly increased by pre|CISION enabling, specifically the maximum tolerated dose of pre|CISION exatecan (AVA6103) observed is 75 times that of conventional exatecan in a daily dosing regimen"

75x. You can say whatever you damn well like at the preclinical stage as they did with AVA6000. The problem is presenting the evidence to your peers to be reviewed. If you can't do that your drug will be stuck at Phase 1 indefinitely.

[baldrick1] 24/10/2024 07:16

Yes very nice news..I bought in again 3days ago .Should make more profits for my charity account.

[ozzmosiz] 24/10/2024 07:13

Very nice RNS

[dillydally2] 24/10/2024 06:30

Dilutions coming

[idle jack] 23/10/2024 16:40

I've been in Tempus AI since just after ipo and have dabbled in avct back in the Covid days. Tem deal has the potential to unlock huge access to data concerning what avct are trying to develop. Not so sure it's the AI flavour of the month element at the moment which will no doubt develop, more the database, that would be cumbersome for anyone else to develop. But the AI will certainly come to fruition. Top owner that founded groupon and huge institutional investor support (inc Google). Good move that and I hope it accelerates avct as they are doing good work.

[amanitaangelicus] 23/10/2024 12:46

Fieldhouse ...glad you.ve seen the potential of AI. Speed, knowledge ...human brains can't compete. Mare for humanity going fwd. No jobs? Hey ho. I can see a Luddite movement beginning.

[amanitaangelicus] 23/10/2024 12:44

Whitey ... how's it gannin me ol' fruitcake? Are you still in that crackpipe circle? Smoke on dude.

[pwhite73] 23/10/2024 11:54

Aman - "I think Avacta knows that the Doli / FAP idea works, looks very safe but the efficacy in terms of halting C is actually poor. Why do I think this? Their recent joint agreement they announced the other day - better warheads"

After all these years this clueless Muppet still has no idea what's going on. The efficacy is not poor. Dox is the most powerful anti-cancer drug in the world. What is wrong is preCISION, there is no warhead that releases DOX only into the tumour when it comes into contact with FAP. In fact no such warheads exist right across the oncology sector.